Insider Transactions in Q3 2022 at Nektar Therapeutics (NKTR)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 23
2022
|
Myriam Curet Director |
SELL
Open market or private sale
|
Direct |
4,198
-11.67%
|
$12,594
$3.16 P/Share
|
|
Sep 23
2022
|
Jeffrey Robert Ajer Director |
SELL
Open market or private sale
|
Direct |
4,198
-9.83%
|
$12,594
$3.16 P/Share
|
|
Sep 22
2022
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
15,300
-2.88%
|
$15,300
$1.93 P/Share
|
|
Sep 16
2022
|
Roy A Whitfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+3.98%
|
-
|
|
Sep 16
2022
|
R Scott Greer Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+3.25%
|
-
|
|
Sep 16
2022
|
Karin Eastham Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+30.51%
|
-
|
|
Sep 16
2022
|
Myriam Curet Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+22.09%
|
-
|
|
Sep 16
2022
|
Robert Chess |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+4.19%
|
-
|
|
Sep 16
2022
|
Diana Brainard Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+26.32%
|
-
|
|
Sep 16
2022
|
Jeffrey Robert Ajer Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+19.28%
|
-
|
|
Sep 13
2022
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
21,267
-62.0%
|
$63,801
$3.61 P/Share
|
|
Aug 18
2022
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
73,716
-18.39%
|
$294,864
$4.65 P/Share
|
|
Aug 16
2022
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
10,560
-2.57%
|
$42,240
$4.76 P/Share
|
|
Aug 16
2022
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,189
-1.12%
|
$12,756
$4.76 P/Share
|
|
Aug 16
2022
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,006
-0.6%
|
$8,024
$4.76 P/Share
|
|
Aug 16
2022
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
13,759
-1.33%
|
$55,036
$4.76 P/Share
|
|
Aug 15
2022
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+24.71%
|
-
|
|
Aug 15
2022
|
Mark Andrew Wilson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,938
+36.85%
|
-
|
|
Aug 15
2022
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,938
+33.0%
|
-
|
|
Aug 15
2022
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
410,625
+28.47%
|
-
|